Disruptive Pharma

We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma MMC).
By a clever amorphous formulation of already approved active pharmaceutical ingredients (APIs) or new chemical entities (NCEs) into Pharma MMC platform we can realize novel and safe improved or therapeutically equivalent drug products.
Our goal is to maximize the potential of the Company by harnessing the potential of our continuously expanding pool of high-performing, safe and IP-protected drug products based on Pharma MMC.

MMC Technology

Development of improved products going into clinical trials

Disruptive Pharma uses its groundbreaking Pharma MMC technology is to build a pipeline of improved versions of approved drugs within selected disease areas. Our first pipeline project is expected to enter clinical trials during 2024. More to come in the future!
The Pharma MMC technology is especially suited for addressing poor bioavailability, and potentially gastro-intestinal toxicity issues, that APIs with poor water solubility may have.

Partner Collaborations

Within the drug enablement business area, we offer different ways of working together;
• Licensing agreements – developing enabling formulations of partner assets
• Fee for service contracts – Technology provider and feasibility trials
• Co-development of partner assets – Mutually agreed development programs

At present we are working with undisclosed industrial and academic partners. Disruptive Pharma is a member in Swedish Drug Delivery Center (SweDeliver) and Additive manufacturing for life sciences (AM4Life) which both are a VINNOVA competence centre.

Team Pharma

The Company, headed by CEO Peter Åsberg, have advanced the development of Pharma MMC drug formulations towards commercial drug products at a high pace. Our development team is headed by Malin Vågerö Director R&D. Tuulikki Lindmark is responsible for pharmaceutical product development and CMC. Manufacturing and scale-up is headed by M.Sc. Tobias Assander. The R&D team consists of highly skilled individuals in drug development, drug formulation and analytical chemistry.
Management is supported by industry experts with extensive experience within patent strategy, business development, regulatory strategy, pharmaceutical quality and clinical development.